Orexo´s partner Gesynta Pharma granted Orphan Drug Designation by the FDA for OX-MPI (GS-248) for the treatment of systemic sclerosis

UPPSALA, Sweden, April 27, 2022 /PRNewswire/ — Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company´s partner Gesynta Pharma AB which owns all the rights to OX-MPI (GS248), a … Read full article

Leave a Reply

Your email address will not be published.